UT Southwestern Down Syndrome Trial and Research Update

Sat, January 17, 2015

10:00 am - 11:30 am
St. Monica's Catholic Church
9933 Midway Rd
Dallas, TX 75220

Dr. Matt Byerly of UT Southwestern and Down syndrome advocate Paul Watson will provide an update on progress in Down syndrome medical research to improve memory and learning. Dr. Byerly will update us on the Roche Pharmaceuticals Down syndrome trial that he led in DFW last year. He will go on to discuss UT Southwestern's new Down syndrome research project starting in January. This project is a groundbreaking pilot study that will begin treatment during pregnancy for mothers pregnant with a baby with Down syndrome, and continue to treat the child through age 2. It is believed that the medication will improve early learning and memory as well as help the child's brain develop in a more typical fashion. The medication has a long track record of safe human use, and 7 studies in Down syndrome mice have shown it both safe and effective. Paul Watson will wrap up with an overview of current Down syndrome cognitive research progress in the US and internationally.

Dr. Byerly has served as a member of the Food and Drug Administration Psychopharmacologic Drugs Advisory Committee. In 2012, Dr. Byerly joined the UT Southwestern Center for Autism and Developmental Disabilities (CADD), extending his research interest to studying potential pharmacologic treatments for neurodevelopmental disorders. He and colleagues are working to translate recent advances in the treatment of mouse models of fragile X syndrome and Down syndrome to individuals with these conditions. Paul Watson is a parent of a 13 year old with Down syndrome and has led state wide advocacy in special education, employment for those with intellectual disabilities, and Down syndrome medical research efforts.

If you are interested in attending this seminar, please RSVP to Victoria Smith at (214) 267-1374 or victoria@downsyndromedallas.org no later than Wednesday, January 14, 2015. Childcare is not provided.